S&P 500   4,514.66 (-1.36%)
DOW   34,425.74 (-0.62%)
QQQ   380.26 (-2.47%)
AAPL   159.99 (-2.30%)
MSFT   318.84 (-3.23%)
FB   304.65 (-1.85%)
GOOGL   2,816.96 (-1.48%)
AMZN   3,363.49 (-2.15%)
TSLA   1,020.18 (-5.94%)
NVDA   303.04 (-5.67%)
BABA   112.73 (-7.60%)
NIO   31.63 (-12.62%)
CGC   10.07 (-2.80%)
AMD   142.13 (-5.67%)
GE   92.52 (-2.85%)
MU   80.85 (-2.45%)
T   23.49 (+1.91%)
F   19.12 (-3.77%)
DIS   145.16 (-1.39%)
PFE   54.01 (+1.83%)
AMC   27.30 (-9.84%)
ACB   5.82 (-5.21%)
BA   196.97 (-2.67%)
S&P 500   4,514.66 (-1.36%)
DOW   34,425.74 (-0.62%)
QQQ   380.26 (-2.47%)
AAPL   159.99 (-2.30%)
MSFT   318.84 (-3.23%)
FB   304.65 (-1.85%)
GOOGL   2,816.96 (-1.48%)
AMZN   3,363.49 (-2.15%)
TSLA   1,020.18 (-5.94%)
NVDA   303.04 (-5.67%)
BABA   112.73 (-7.60%)
NIO   31.63 (-12.62%)
CGC   10.07 (-2.80%)
AMD   142.13 (-5.67%)
GE   92.52 (-2.85%)
MU   80.85 (-2.45%)
T   23.49 (+1.91%)
F   19.12 (-3.77%)
DIS   145.16 (-1.39%)
PFE   54.01 (+1.83%)
AMC   27.30 (-9.84%)
ACB   5.82 (-5.21%)
BA   196.97 (-2.67%)
S&P 500   4,514.66 (-1.36%)
DOW   34,425.74 (-0.62%)
QQQ   380.26 (-2.47%)
AAPL   159.99 (-2.30%)
MSFT   318.84 (-3.23%)
FB   304.65 (-1.85%)
GOOGL   2,816.96 (-1.48%)
AMZN   3,363.49 (-2.15%)
TSLA   1,020.18 (-5.94%)
NVDA   303.04 (-5.67%)
BABA   112.73 (-7.60%)
NIO   31.63 (-12.62%)
CGC   10.07 (-2.80%)
AMD   142.13 (-5.67%)
GE   92.52 (-2.85%)
MU   80.85 (-2.45%)
T   23.49 (+1.91%)
F   19.12 (-3.77%)
DIS   145.16 (-1.39%)
PFE   54.01 (+1.83%)
AMC   27.30 (-9.84%)
ACB   5.82 (-5.21%)
BA   196.97 (-2.67%)
S&P 500   4,514.66 (-1.36%)
DOW   34,425.74 (-0.62%)
QQQ   380.26 (-2.47%)
AAPL   159.99 (-2.30%)
MSFT   318.84 (-3.23%)
FB   304.65 (-1.85%)
GOOGL   2,816.96 (-1.48%)
AMZN   3,363.49 (-2.15%)
TSLA   1,020.18 (-5.94%)
NVDA   303.04 (-5.67%)
BABA   112.73 (-7.60%)
NIO   31.63 (-12.62%)
CGC   10.07 (-2.80%)
AMD   142.13 (-5.67%)
GE   92.52 (-2.85%)
MU   80.85 (-2.45%)
T   23.49 (+1.91%)
F   19.12 (-3.77%)
DIS   145.16 (-1.39%)
PFE   54.01 (+1.83%)
AMC   27.30 (-9.84%)
ACB   5.82 (-5.21%)
BA   196.97 (-2.67%)
NASDAQ:CDTX

Cidara Therapeutics Insider Trades

$1.54
+0.09 (+6.21%)
(As of 12/3/2021 01:58 PM ET)
Add
Compare
Today's Range
$1.48
$1.62
50-Day Range
$1.40
$2.35
52-Week Range
$1.31
$3.15
Volume
13,460 shs
Average Volume
623,231 shs
Market Capitalization
$102.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13

Cidara Therapeutics (NASDAQ:CDTX) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
8.03%

Number Of
Insiders Buying
(Last 12 Months)
3

Amount Of
Insider Buying
(Last 12 Months)
$193.94 K

Number Of
Insiders Selling
(Last 12 Months)
3

Amount Of
Insider Selling
(Last 12 Months)
$16.22 K

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get CDTX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Cidara Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Cidara Therapeutics (NASDAQ CDTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/12/2021Jeffrey SteinCEOBuy50,000$1.59$79,500.00  
11/12/2021Preetam ShahCFOBuy20,000$1.54$30,800.00  
9/13/2021Timothy R FransonDirectorBuy7,000$2.12$14,840.00  
8/18/2021Jeffrey SteinCEOBuy40,000$1.72$68,800.00  
4/1/2021Jessica OienGeneral CounselSell1,177$2.66$3,130.826,141  
4/1/2021Neil AbdollahianInsiderSell1,469$2.66$3,907.5455,440  
4/1/2021Paul DaruwalaCOOSell593$2.66$1,577.3849,724  
1/5/2021Jessica OienGeneral CounselSell824$2.06$1,697.446,141  
1/5/2021Neil AbdollahianInsiderSell2,868$2.06$5,908.0855,440  
11/10/2020James E. LevineCFOBuy50,000$2.01$100,500.00  
1/3/2020Neil AbdollahianinsiderSell2,340$3.42$8,002.8053,532  
1/2/2020Jessica OienGeneral CounselSell834$3.86$3,219.246,965  
10/2/2019Paul DaruwalaCOOSell3,295$1.88$6,194.6055,872  
10/1/2019Neil AbdollahianInsiderSell7,284$1.98$14,422.3249,588  
9/27/2019Jessica OienGeneral CounselSell1,001$1.86$1,861.867,799  
9/24/2019James E LevineCFOBuy30,000$1.91$57,300.00205,000  
9/24/2019Jeffrey SteinCEOBuy52,500$1.91$100,275.00282,320  
3/8/2019Neil AbdollahianInsiderSell2,300$2.44$5,612.0030,472  
3/7/2019Paul DaruwalaCOOSell2,240$2.55$5,712.0049,567  
5/23/2018Jeffrey SteinCEOBuy212,766$4.70$1,000,000.20  
11/15/2017Target N V BiotechMajor ShareholderBuy60,000$7.57$454,200.002,295,272  
9/12/2017Jeffrey SteinCEOBuy7,350$6.79$49,906.5051,851  
6/7/2017Taylor SandisonInsiderBuy20,000$5.90$118,000.00  
6/5/2017Jeffrey SteinCEOBuy15,000$5.95$89,250.00  
3/31/2017Jeffrey SteinCEOBuy12,900$7.75$99,975.00  
3/31/2017Kevin ForrestInsiderBuy12,500$7.75$96,875.00  
5/20/2016Jeffrey SteinCEOBuy4,310$11.51$49,608.1012,100  
5/20/2016Kevin ForrestCFOBuy4,356$11.53$50,224.6858,253  
11/25/2015Jeffrey SteinCEOBuy6,700$15.09$101,103.006,700  
11/23/2015Kevin ForrestCFOBuy7,087$14.23$100,848.0151,719  
4/20/2015Timothy R FransonDirectorBuy4,000$16.00$64,000.00  
(Data available from 1/1/2013 forward)












Cidara Therapeutics (NASDAQ:CDTX) Insider Trade Frequently Asked Questions

Who is on Cidara Therapeutics's Insider Roster?

The list of insiders at Cidara Therapeutics includes James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian, Paul Daruwala, Preetam Shah, and Timothy R Franson.Learn more on CDTX's insiders

What percentage of Cidara Therapeutics stock is owned by insiders?

8.03% of Cidara Therapeutics stock is owned by insiders. Learn more on CDTX's insider holdings

Which Cidara Therapeutics insiders have been buying company stock?

The following insiders have purchased Cidara Therapeutics stock in the last 24 months: James E. Levine ($100,500.00), Jeffrey Stein ($148,300.00), Preetam Shah ($30,800.00), and Timothy R Franson ($14,840.00).

How much insider buying is happening at Cidara Therapeutics?

Insiders have purchased a total of 167,000 Cidara Therapeutics shares in the last 24 months for a total of $294,440.00 bought.

Which Cidara Therapeutics insiders have been selling company stock?

The following insiders have sold Cidara Therapeutics stock in the last 24 months: Jessica Oien ($8,047.50), Neil Abdollahian ($17,818.42), and Paul Daruwala ($1,577.38).

How much insider selling is happening at Cidara Therapeutics?

Insiders have sold a total of 10,105 Cidara Therapeutics shares in the last 24 months for a total of $27,443.30 sold.

This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.